The number of colorectal cancer cases in people under 50 is rising worldwide, especially in high-income countries. Possible ...

Asciminib shows superior tolerability over nilotinib in newly diagnosed CML-CP patients, reducing treatment discontinuation ...

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers ...

According to the results, olverembatinib demonstrated high complete remission (CR) and complete molecular response (CMR) rates ... approved in China for the treatment of patients with CML in chronic ...

Early molecular responses were achieved in 71.9% of patients, with continuous improvements observed over 24 months. (After a median follow-up of 34 months, 64% of the study population achieved a ...

HOUSTON -- An early molecular or cytogenetic response correlated with better long-term survival in heavily pretreated chronic-phase chronic myeloid leukemia (CML) treated with the BCR-ABL ...

Patients who achieved major molecular response at 3 months achieved better 4-year PFS (80% vs. 54%; P = .001) and numerically higher 4-year OS (89% vs. 80%) than those who did not.

A 2017 study found that achieving early major molecular response predicted better outcomes for people with CML and may be useful in helping doctors identify whether alternate TKI medications are ...

Early and deep molecular responses achieved with frontline asciminib in chronic phase CML – interim results from ALLG CML13 Ascend-CM. Presented at ASH 2022. December 10-13, 2022. Abstract 79.

They investigated the role of early molecular response (EMR) in the long-term outcome based on the first-line TKI. 2 “Treatment goal is the deepest molecular response,” the authors wrote.

A randomized phase 3 trial designed to evaluate asciminib as treatment for certain patients with chronic myeloid leukemia met its primary endpoint, according to the agent’s manufacturer ...

Used together, Bio-Rad's system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).